RecruitingNot applicableNCT06150742

Nafamostat Efficacy in Phase 3 Registrational CRRT Study

Studying Acute graft versus host disease

Last synced from ClinicalTrials.gov May 2, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Talphera, Inc
Intervention: Niyad (nafamostat mesylate)(device)
Enrollment: 70 target
Eligibility: 18-80 years · All sexes
Timeline: 2024 – 2025

Study locations (10)

University of California Los Angeles, Los Angeles, California, United States
AdventHealth, Orlando, Florida, United States
Henry Ford Health, Detroit, Michigan, United States
University of New Mexico, Albuquerque, New Mexico, United States
Northwell Health, Great Neck, New York, United States
Mount Sinai, New York, New York, United States
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Medical University of South Carolina, Charleston, South Carolina, United States
Baylor University Medical Center, Dallas, Texas, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06150742 on ClinicalTrials.gov

Other trials for Acute graft versus host disease

Additional recruiting or active studies for the same condition.

See all trials for Acute graft versus host disease →

← Back to all trials